Cara Therapeutics announces positive results in trial of treatment for chronic kidney diseaseMarket Watch • 12/03/19
Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe PruritusGlobeNewsWire • 12/03/19
Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of MedicineGlobeNewsWire • 11/11/19
Cara Therapeutics Q3 Update: Forget the Financials and Focus on the PipelineThe Motley Fool • 11/06/19
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19
Cara Therapeutics Announces Completion of Interim Statistical Assessment and Small Increase in Target Enrollment for KALM-2 Phase 3 Global Trial of KORSUVA™ Injection in Hemodialysis Patients with PruritusGlobeNewsWire • 10/14/19
Cara Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/26/19
Cara Therapeutics Enters into Commercial License Agreement with Enteris BioPharma, Inc. for Peptelligence® Oral Formulation TechnologyGlobeNewsWire • 08/21/19
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Cara Therapeutics Inc (CARA) CFO & Chief Strategy Officer Mani Mohindru Sold $935,775 of SharesGuruFocus • 07/17/19
Cara's Second Half Catalyst Has The Potential To Change The Scope Of The Biotech ForeverSeeking Alpha • 06/11/19